BiologicsRegulatory

BIOMATLANTE receives MDSAP Accreditation

Nantes, France – Quality and Regulatory

Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP* accreditation on the new ISO 13485:2016 Certificate.

The Medical Device Single Audit Program (MDSAP) is an international program for assessing the quality management systems of medical device manufacturers who market their products in Australia, Brazil, Canada, Japan and/or the United States. With MDSAP, a single regulatory audit conducted by an MDSAP recognized auditing organization will satisfy the requirements of multiple regulatory authorities.

Among other benefits, the compliance of the quality management system with the requirements of this program allows harmonization of audit requirements, universal audit reporting and better knowledge of international regulatory requirements. This new certificate is also mandatory in 2019 to maintain or apply medical device licenses on the Canadian market.

Biomatlante is now part of the very restrictive club of MDSAP accredited organizations. We pride ourselves to constantly work on improving our quality management system in order to provide medical devices that consistently meet customer demand and applicable regulatory requirements. MDSAP represents a new step in this continuous effort.

The new certificate also validates the ISO 13485 version 2016 and shows our willingness to make a successful transition to the new Medical Device Regulation (MDR) 2017/745/CEE.

* Medical Device Single Audit Program

About BIOMATLANTE, experts in bone regeneration Based near Nantes, Western France, Biomatlante is a world leader in synthetic bone regenerative technologies, providing innovative products for orthopedic, traumatological, spine and dental applications. Biomatlante markets its innovative products in more than 50 countries worldwide. Biomatlante prides itself on staying abreast of an ever evolving market, thus ensuring its products meet the demanding requirements of surgeons and healthcare companies around the globe. Thanks to a robust research and development department, Biomatlante has been granted various patents and licenses covering both biomaterials and new associated technologies, based on its MBCP® Proprietary Technology.

Contact – Nadine Valentin, Marketing Manager, Biomatlante, marketing@biomatlante.com

Tags

Mason Krell

Mason began his career in the Orthopedic Industry in 2017 when he joined The De Angelis Group as a Research Manager. He has developed a strong network within the industry and is very dedicated to helping companies maximize opportunities and disrupt markets.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close
Themed By Curio Display Cabinets